INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8201, 691, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8202, 692, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8203, 4210, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8204, 4325, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8205, 4894, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8206, 4903, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8207, 4904, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8208, 4905, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8209, 4906, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8210, 4930, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8211, 6077, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8212, 8101, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8213, 8102, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8214, 14075, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8215, 14076, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8216, 14080, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8217, 15559, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8218, 16787, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8219, 17956, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8220, 17957, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8221, 18347, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8222, 19075, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8223, 19077, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8224, 19078, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8225, 19079, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8226, 19085, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8227, 19630, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8228, 22672, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8229, 22676, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8230, 22677, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8231, 22679, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8232, 22680, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8233, 26297, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8234, 28488, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8235, 28489, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8236, 28490, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8237, 28491, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8238, 28492, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8239, 30008, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8240, 30543, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8241, 33203, 'Metronidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8242, 0, 'Metyrosine', 'Extrapyramidal Symptoms', 'Extrapyramidal symptoms (EPS) have occurred in approximately 10% of patients receiving metyrosine.  EPS include drooling, speech difficulty, and tremor.  Trismus and parkinsonian syndrome have been reported.  Therapy with metyrosine should be administered cautiously in patients with or predisposition to EPS or Parkinson''s disease.  Dosage reduction or discontinuation of metyrosine may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8243, 0, 'Metyrosine', 'Mental Disorders', 'Anxiety, excitability, and psychic disturbances such as hallucinations, disorientation/confusion, emotional instability, and depression have occurred in patients receiving metyrosine.  Therapy with metyrosine should be administered cautiously in patients with psychiatric and/or emotional disorders.  Dosage reduction may be appropriate.  Clinical monitoring of emotional and psychiatric status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8244, 0, 'Metyrosine', 'Kidney Diseases', 'Metyrosine is primarily eliminated by the kidney.  The serum concentration of metyrosine may be increased in patients with renal impairment.  Therapy with metyrosine should be administered cautiously in patient with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8245, 1779, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8246, 3289, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8247, 3506, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8248, 5813, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8249, 5822, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8250, 8128, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8251, 8133, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8252, 8134, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8253, 8137, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8254, 8138, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8255, 8139, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8256, 8290, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8257, 8494, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8258, 17067, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8259, 20110, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8260, 20115, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8261, 20125, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8262, 22698, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8263, 22702, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8264, 22705, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8265, 22709, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8266, 22711, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8267, 22712, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8268, 22713, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8269, 22715, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8270, 22716, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8271, 22915, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8272, 23154, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8273, 23169, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8274, 23170, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8275, 23171, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8276, 24704, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8277, 32932, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8278, 33396, 'Miconazole', 'Liver Diseases', 'The use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver.  Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8279, 1779, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8280, 3289, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8281, 3506, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8282, 5813, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8283, 5822, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8284, 8128, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8285, 8133, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8286, 8134, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8287, 8137, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8288, 8138, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8289, 8139, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8290, 8290, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8291, 8494, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8292, 17067, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8293, 20110, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8294, 20115, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8295, 20125, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8296, 22698, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8297, 22702, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8298, 22705, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8299, 22709, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8300, 22711, 'Miconazole', 'Hyperlipidemias', 'Elevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil).  These increases are reversible upon discontinuation of miconazole therapy.  Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.', '1', '', 'DDInter', 0);
